Hangzhou Biotest Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,390	1,476	1,591	1,907	1,940	1,368
Short-Term Investments	-	-	-	10	-	-
Trading Asset Securities	13.93	13.76	60.26	-	100.06	360.84
Cash & Short-Term Investments	1,404	1,489	1,651	1,917	2,040	1,729
Cash Growth	-13.76%	-9.80%	-13.88%	-6.01%	18.02%	561.86%
Accounts Receivable	86.96	89.37	97.46	61.89	38.82	146.91
Other Receivables	2.18	3.44	4.27	2.8	1.6	8.32
Receivables	89.13	92.81	101.73	64.68	40.42	155.23
Inventory	71.73	69.68	73.4	99.32	135.2	141.7
Other Current Assets	15.94	9.59	51.57	5.37	19.6	7.2
Total Current Assets	1,580	1,661	1,878	2,087	2,235	2,033
Property, Plant & Equipment	534.74	540.87	408.81	261.58	244.68	231.02
Long-Term Investments	60.53	31.41	19.3	2.84	40	40
Other Intangible Assets	267.89	269.31	275.16	208.71	213.71	20.35
Long-Term Deferred Tax Assets	13.99	10.1	11.8	14.44	13.16	3.01
Long-Term Deferred Charges	-	-	-	0.11	0.21	0.29
Other Long-Term Assets	28.51	26.25	9.15	5.08	4.54	104.13
Total Assets	2,486	2,539	2,602	2,580	2,752	2,432
Accounts Payable	65.47	98.67	56.45	58.35	88.72	224.32
Accrued Expenses	6.6	15.55	19.08	20.02	25.94	26.32
Short-Term Debt	0.44	0.49	0.44	0.59	0.35	5.64
Current Portion of Leases	-	-	-	2.45	5.1	2.28
Current Income Taxes Payable	1.78	3.73	0.02	-	-	39
Current Unearned Revenue	11.74	15.16	7.39	47.16	44.68	18.56
Other Current Liabilities	25.95	24.38	95.23	20.85	6.28	1.44
Total Current Liabilities	111.98	157.98	178.62	149.43	171.08	317.56
Long-Term Leases	-	-	-	-	2.19	4.55
Long-Term Unearned Revenue	9.75	10.19	11.17	8.69	6.43	1.25
Long-Term Deferred Tax Liabilities	-	-	-	0.71	1.16	-
Other Long-Term Liabilities	-	-	-	-	8.43	-
Total Liabilities	121.73	168.17	189.79	158.82	189.29	323.36
Common Stock	149.33	149.33	106.67	106.67	106.67	106.67
Additional Paid-In Capital	752.28	751.68	790.45	813.33	814.94	814.94
Retained Earnings	1,475	1,486	1,543	1,510	1,638	1,185
Treasury Stock	-18.07	-18.07	-31.61	-14.76	-	-
Comprehensive Income & Other	1.54	1.24	0.94	-0.36	1.21	0.7
Total Common Equity	2,360	2,370	2,409	2,415	2,561	2,107
Minority Interest	3.78	1.47	2.87	5.51	1.04	1.05
Shareholders' Equity	2,364	2,371	2,412	2,421	2,562	2,108
Total Liabilities & Equity	2,486	2,539	2,602	2,580	2,752	2,432
Total Debt	0.44	0.49	0.44	3.04	7.64	12.47
Net Cash (Debt)	1,403	1,489	1,651	1,914	2,032	1,716
Net Cash Growth	-13.73%	-9.80%	-13.77%	-5.81%	18.43%	586.22%
Net Cash Per Share	9.68	10.28	11.20	12.83	13.60	14.15
Filing Date Shares Outstanding	145.83	102.38	148.78	146.38	149.33	149.33
Total Common Shares Outstanding	145.83	102.38	148.78	148.7	149.33	149.33
Working Capital	1,468	1,504	1,699	1,937	2,064	1,715
Book Value Per Share	16.19	23.15	16.20	16.24	17.15	14.11
Tangible Book Value	2,093	2,100	2,134	2,207	2,348	2,087
Tangible Book Value Per Share	14.35	20.52	14.35	14.84	15.72	13.97
Buildings	-	-	306.67	193.65	194.71	189.13
Machinery	-	-	96.17	90.92	81.61	66.19
Construction In Progress	-	-	87.23	39.65	9.85	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.